ASEAN Cancer Therapeutics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
No. of Pages: 150 | Report Code: BMIRE00031439 | Category: Life Sciences
No. of Pages: 150 | Report Code: BMIRE00031439 | Category: Life Sciences
The cancer therapeutics market size is expected to reach US$ 20,612.38 million by 2031 from US$ 7,269.43 million in 2024. The market is estimated to record a CAGR of 13.9 % from 2025 to 2031.
The increasing incidence of cancer—fueled by an aging population; urbanization; and lifestyle changes such as smoking, unhealthy diets, and reduced physical activity—boost the market growth in these countries. Government initiatives and public–private partnerships focused on cancer awareness, prevention, and early detection are further accelerating market growth. In addition, the rise in health insurance coverage, along with an increasing middle-class population in these countries, results in better access to life-saving treatments. Many multinational pharmaceutical companies are investing in the region, which further aids in the rapid expansion of the cancer therapeutics market across ASEAN countries.
Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.
A number of demographic, socioeconomic, and healthcare-related variables have contributed to the steady rise in the demand for cancer treatments in ASEAN nations. Rising cancer rates, aging populations, changing lifestyles, improvements in medical technology, and unequal access to care are some of these causes.
According to the GLOBOCAN in 2023, Indonesia reported ~ 500,000 new cancer cases and approximately 300,000 cancer-related deaths. The country's large and growing population, coupled with lifestyle factors such as smoking, dietary habits, and pollution, contribute to the rising cancer incidence. In recent years, the Indonesian government has made strides to improve the country's healthcare system, with efforts made to enhance cancer awareness, promote screening and early detection programs, and make affordable treatment more accessible. Initiatives such as the National Cancer Control Program aim to address challenges associated with the growing cancer burden by improving diagnosis and treatment options.
The cancer therapeutics market in the Philippines is characterized by a strong demand for innovative therapies driven by product launches in targeted treatments, immunotherapies, and biologics. Government initiatives—particularly through the National Integrated Cancer Control Act and PhilHealth—have played a pivotal role in improving access to cancer care services and treatments. However, challenges such as the high cost of drugs and limitations associated with the existing healthcare system limit the market growth to a certain extent. As the Philippines continues to develop its healthcare infrastructure and expand access to cancer care, the cancer therapeutics market is likely to grow and evolve in the coming years, offering hope for cancer patients and their families.
Based on region, ASEAN cancer therapeutics market is further segmented into Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh, New Zealand, and the Rest of ASEAN. Singapore held the largest share in 2024.
The cancer therapeutics market in Singapore is driven by ongoing research and innovation efforts, and government support. With a population of over 5 million, Singapore faces a rising incidence of cancer, which is one of the leading causes of death in the country. As cancer care continues to evolve globally, Singapore has become a hub for oncology drug development, attracting both international and local pharmaceutical companies to conduct research and introduce new therapies. The cancer therapeutics market in the country is characterized by the burgeoning demand for targeted therapies, immunotherapies, and precision medicine, which have transformed the way the disease is treated, offering more effective and personalized treatment options.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 7,269.43 Million |
| Market Size by 2031 | US$ 20,612.38 Million |
| Global CAGR (2025 - 2031) | 13.9 % |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Therapy Type
|
| Regions and Countries Covered | ASEAN
|
Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie Inc are among the key players operating in the market. These players adopt strategies such as expansion, product innovation, and mergers and acquisitions to stay competitive in the market and offer innovative products to their consumers.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:
The ASEAN Cancer Therapeutics Market is valued at US$ 7,269.43 Million in 2024, it is projected to reach US$ 20,612.38 Million by 2031.
As per our report ASEAN Cancer Therapeutics Market, the market size is valued at US$ 7,269.43 Million in 2024, projecting it to reach US$ 20,612.38 Million by 2031. This translates to a CAGR of approximately 13.9 % during the forecast period.
The ASEAN Cancer Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the ASEAN Cancer Therapeutics Market report:
The ASEAN Cancer Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The ASEAN Cancer Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the ASEAN Cancer Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For ASEAN Cancer Therapeutics Market
